# Ingevity Corp: financial statements, quarterly

NGVT · NYSE · CIK 1653477 · [Materials](/sectors/materials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/ngvt.md) · [Financials](/companies/ngvt/financials.md) · [Filings](/companies/ngvt/filings.md) · [Insiders](/companies/ngvt/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/ngvt/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [446](/filings/0001653477-24-000100.md) | [(105) d](/filings/0001653477-26-000014.md) | [340](/filings/0001653477-25-000091.md) | [391](/filings/0001653477-25-000108.md) | [334](/filings/0001653477-25-000127.md) | [263 d](/filings/0001653477-26-000014.md) | [248](/filings/0001653477-26-000035.md) | [332](/filings/0001653477-26-000047.md) | [333](/filings/0001653477-25-000127.md) | [255 d](/filings/0001653477-26-000014.md) | [258](/filings/0001653477-26-000035.md) | [314](/filings/0001653477-26-000047.md) |
| Cost of revenue | $m | [317](/filings/0001653477-24-000100.md) | [(138) d](/filings/0001653477-26-000014.md) | [240](/filings/0001653477-25-000091.md) | [267](/filings/0001653477-25-000108.md) | [202](/filings/0001653477-25-000127.md) | [163 d](/filings/0001653477-26-000014.md) | [136](/filings/0001653477-26-000035.md) | [204](/filings/0001653477-26-000047.md) | [199](/filings/0001653477-25-000127.md) | [167 d](/filings/0001653477-26-000014.md) | [142](/filings/0001653477-26-000035.md) | [175](/filings/0001653477-26-000047.md) |
| Gross profit | $m | [129](/filings/0001653477-24-000100.md) | [32.6 d](/filings/0001653477-26-000014.md) | [99.7](/filings/0001653477-25-000091.md) | [123](/filings/0001653477-25-000108.md) | [132](/filings/0001653477-25-000127.md) | [99.9 d](/filings/0001653477-26-000014.md) | [112](/filings/0001653477-26-000035.md) | [128](/filings/0001653477-26-000047.md) | [134](/filings/0001653477-25-000127.md) | [87.8 d](/filings/0001653477-26-000014.md) | [116](/filings/0001653477-26-000035.md) | [139](/filings/0001653477-26-000047.md) |
| Research and development | $m | [7.8](/filings/0001653477-24-000100.md) | [0.8 d](/filings/0001653477-26-000014.md) | [6.8](/filings/0001653477-25-000091.md) | [7.3](/filings/0001653477-25-000108.md) | [6.2](/filings/0001653477-25-000127.md) | [6.5 d](/filings/0001653477-26-000014.md) | [7.0](/filings/0001653477-26-000035.md) | [7.0](/filings/0001653477-26-000047.md) | [7.0](/filings/0001653477-25-000127.md) | [7.4 d](/filings/0001653477-26-000014.md) | [6.7](/filings/0001653477-26-000035.md) | [6.1](/filings/0001653477-26-000047.md) |
| Selling, general and administrative | $m | [40.0](/filings/0001653477-24-000100.md) | [21.5 d](/filings/0001653477-26-000014.md) | [47.2](/filings/0001653477-25-000091.md) | [41.4](/filings/0001653477-25-000108.md) | [37.9](/filings/0001653477-25-000127.md) | [38.3 d](/filings/0001653477-26-000014.md) | [41.9](/filings/0001653477-26-000035.md) | [43.6](/filings/0001653477-26-000047.md) | [44.1](/filings/0001653477-25-000127.md) | [41.6 d](/filings/0001653477-26-000014.md) | [40.7](/filings/0001653477-26-000035.md) | [39.0](/filings/0001653477-26-000047.md) |
| Operating income | $m | [110](/filings/0001653477-24-000100.md) | [88.2 d](/filings/0001653477-26-000014.md) | [76.9](/filings/0001653477-24-000058.md) | [101](/filings/0001653477-24-000082.md) | [110](/filings/0001653477-24-000100.md) | [138 d](/filings/0001653477-26-000014.md) | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [6.9](/filings/0001653477-24-000100.md) | [(8.3) d](/filings/0001653477-26-000014.md) | [(15.9)](/filings/0001653477-25-000091.md) | [(50.9)](/filings/0001653477-25-000108.md) | [6.5](/filings/0001653477-25-000127.md) | [4.5 d](/filings/0001653477-26-000014.md) | [8.5](/filings/0001653477-26-000035.md) | [4.8](/filings/0001653477-26-000047.md) | [21.4](/filings/0001653477-25-000127.md) | [(26.6) d](/filings/0001653477-26-000014.md) | [6.8](/filings/0001653477-26-000035.md) | [10.9](/filings/0001653477-26-000047.md) |
| Net income | $m | [25.2](/filings/0001653477-24-000100.md) | [(117) d](/filings/0001653477-26-000014.md) | [(56.0)](/filings/0001653477-25-000127.md) | [(284)](/filings/0001653477-25-000127.md) | [(107)](/filings/0001653477-25-000127.md) | [16.6 d](/filings/0001653477-26-000014.md) | [20.5](/filings/0001653477-26-000047.md) | [(147)](/filings/0001653477-26-000047.md) | [43.5](/filings/0001653477-25-000127.md) | [(84.6) d](/filings/0001653477-26-000014.md) | [59.8](/filings/0001653477-26-000047.md) | [35.3](/filings/0001653477-26-000047.md) |
| Diluted EPS | $ per share | [0.69](/filings/0001653477-24-000100.md) | not reported | [(1.54)](/filings/0001653477-25-000091.md) | [(7.81)](/filings/0001653477-25-000108.md) | [(2.94)](/filings/0001653477-25-000127.md) | not reported | [0.56](/filings/0001653477-26-000035.md) | [(4.02)](/filings/0001653477-26-000047.md) | [1.18](/filings/0001653477-25-000127.md) | not reported | [1.66](/filings/0001653477-26-000035.md) | [1.00](/filings/0001653477-26-000047.md) |
| Basic EPS | $ per share | [0.70](/filings/0001653477-24-000100.md) | not reported | [(1.54)](/filings/0001653477-25-000091.md) | [(7.81)](/filings/0001653477-25-000108.md) | [(2.95)](/filings/0001653477-25-000127.md) | not reported | [0.56](/filings/0001653477-26-000035.md) | [(4.02)](/filings/0001653477-26-000047.md) | [1.20](/filings/0001653477-25-000127.md) | not reported | [1.70](/filings/0001653477-26-000035.md) | [1.02](/filings/0001653477-26-000047.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [84.5](/filings/0001653477-24-000100.md) | [95.9](/filings/0001653477-26-000014.md) | [88.5](/filings/0001653477-25-000091.md) | [107](/filings/0001653477-25-000108.md) | [136](/filings/0001653477-25-000127.md) | [68.0](/filings/0001653477-26-000014.md) | [71.5](/filings/0001653477-26-000035.md) | [76.9](/filings/0001653477-26-000047.md) | [83.4](/filings/0001653477-25-000127.md) | [78.1](/filings/0001653477-26-000047.md) | [95.4](/filings/0001653477-26-000035.md) | [97.4](/filings/0001653477-26-000047.md) |
| Current assets | $m | [735](/filings/0001653477-23-000057.md) | [659](/filings/0001653477-25-000015.md) | [669](/filings/0001653477-24-000058.md) | [686](/filings/0001653477-24-000082.md) | [637](/filings/0001653477-24-000100.md) | [493](/filings/0001653477-26-000014.md) | [530](/filings/0001653477-25-000091.md) | [536](/filings/0001653477-25-000108.md) | [522](/filings/0001653477-25-000127.md) | [454](/filings/0001653477-26-000047.md) | [582](/filings/0001653477-26-000035.md) | [544](/filings/0001653477-26-000047.md) |
| Total assets | $m | [2,767](/filings/0001653477-23-000057.md) | [2,623](/filings/0001653477-25-000015.md) | [2,567](/filings/0001653477-24-000058.md) | [2,276](/filings/0001653477-24-000082.md) | [2,212](/filings/0001653477-24-000100.md) | [2,023](/filings/0001653477-26-000014.md) | [2,056](/filings/0001653477-25-000091.md) | [1,878](/filings/0001653477-25-000108.md) | [1,834](/filings/0001653477-25-000127.md) | [1,651](/filings/0001653477-26-000047.md) | [1,650](/filings/0001653477-26-000035.md) | [1,538](/filings/0001653477-26-000047.md) |
| Current liabilities | $m | [305](/filings/0001653477-23-000057.md) | [363](/filings/0001653477-25-000015.md) | [352](/filings/0001653477-24-000058.md) | [358](/filings/0001653477-24-000082.md) | [361](/filings/0001653477-24-000100.md) | [264](/filings/0001653477-26-000014.md) | [265](/filings/0001653477-25-000091.md) | [393](/filings/0001653477-25-000108.md) | [412](/filings/0001653477-25-000127.md) | [341](/filings/0001653477-26-000047.md) | [409](/filings/0001653477-26-000035.md) | [338](/filings/0001653477-26-000047.md) |
| Total liabilities | $m | [2,048](/filings/0001653477-23-000057.md) | [1,992](/filings/0001653477-25-000015.md) | [1,999](/filings/0001653477-24-000058.md) | [1,991](/filings/0001653477-24-000082.md) | [1,997](/filings/0001653477-24-000100.md) | [1,827](/filings/0001653477-26-000014.md) | [1,822](/filings/0001653477-25-000091.md) | [1,757](/filings/0001653477-25-000108.md) | [1,696](/filings/0001653477-25-000127.md) | [1,621](/filings/0001653477-26-000047.md) | [1,611](/filings/0001653477-26-000035.md) | [1,491](/filings/0001653477-26-000047.md) |
| Current portion of debt | $m | [3.0](/filings/0001653477-23-000057.md) | [84.4](/filings/0001653477-25-000015.md) | [84.7](/filings/0001653477-24-000058.md) | [103](/filings/0001653477-24-000082.md) | [101](/filings/0001653477-24-000100.md) | [61.3](/filings/0001653477-26-000014.md) | [60.4](/filings/0001653477-25-000091.md) | [94.7](/filings/0001653477-25-000108.md) | [102](/filings/0001653477-25-000127.md) | [47.1](/filings/0001653477-26-000047.md) | [122](/filings/0001653477-26-000035.md) | [144](/filings/0001653477-26-000047.md) |
| Shareholders' equity | $m | [719](/filings/0001653477-24-000100.md) | [631](/filings/0001653477-26-000014.md) | [568](/filings/0001653477-25-000127.md) | [285](/filings/0001653477-25-000127.md) | [215](/filings/0001653477-25-000127.md) | [195](/filings/0001653477-26-000047.md) | [235](/filings/0001653477-26-000047.md) | [121](/filings/0001653477-26-000047.md) | [138](/filings/0001653477-25-000127.md) | [29.7](/filings/0001653477-26-000047.md) | [38.9](/filings/0001653477-26-000047.md) | [46.9](/filings/0001653477-26-000047.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [105 d](/filings/0001653477-24-000100.md) | [46.2 d](/filings/0001653477-26-000014.md) | [(12.1)](/filings/0001653477-25-000091.md) | [29.7 d](/filings/0001653477-25-000108.md) | [46.5 d](/filings/0001653477-25-000127.md) | [64.5 d](/filings/0001653477-26-000014.md) | [25.4](/filings/0001653477-26-000035.md) | [79.0 d](/filings/0001653477-26-000047.md) | [130 d](/filings/0001653477-25-000127.md) | [97.1 d](/filings/0001653477-26-000014.md) | [(2.0)](/filings/0001653477-26-000035.md) | [(13.8) d](/filings/0001653477-26-000047.md) |
| Capital expenditure | $m | [33.5 d](/filings/0001653477-24-000100.md) | [29.2 d](/filings/0001653477-26-000014.md) | [16.6](/filings/0001653477-25-000091.md) | [18.1](/filings/0001653477-25-000108.md) | [18.0 d](/filings/0001653477-25-000127.md) | [24.9 d](/filings/0001653477-26-000014.md) | [10.0](/filings/0001653477-26-000035.md) | [12.2](/filings/0001653477-25-000108.md) | [11.9 d](/filings/0001653477-25-000127.md) | [23.6 d](/filings/0001653477-26-000014.md) | [10.3](/filings/0001653477-26-000035.md) | [10.3 d](/filings/0001653477-26-000047.md) |
| Share repurchases | $m | [0.0 d](/filings/0001653477-24-000100.md) | [0.0 d](/filings/0001653477-26-000014.md) | [0.0](/filings/0001653477-24-000058.md) | [0.0 d](/filings/0001653477-24-000082.md) | [0.0 d](/filings/0001653477-25-000127.md) | [0.0 d](/filings/0001653477-26-000014.md) | [0.0](/filings/0001653477-26-000035.md) | [0.0 d](/filings/0001653477-26-000047.md) | [25.2 d](/filings/0001653477-25-000127.md) | [31.1 d](/filings/0001653477-26-000014.md) | [52.3](/filings/0001653477-26-000035.md) | [34.5 d](/filings/0001653477-26-000047.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [38.1](/filings/0001653477-23-000057.md) | [37.5](/filings/0001653477-24-000058.md) | [36.6](/filings/0001653477-24-000082.md) | [36.4](/filings/0001653477-24-000100.md) | [36.3](/filings/0001653477-25-000091.md) | [36.3](/filings/0001653477-25-000108.md) | [36.5](/filings/0001653477-25-000127.md) | [36.7](/filings/0001653477-26-000035.md) | [36.5](/filings/0001653477-26-000047.md) | [37.0](/filings/0001653477-25-000127.md) | [36.0](/filings/0001653477-26-000035.md) | [35.3](/filings/0001653477-26-000047.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 34,377,922 at 2026-07-24, from the cover of the [10-Q filed 2026-07-30](/filings/0001653477-26-000047.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:45 ET. No prices; not investment advice.